Дослідження виявило зв'язок між рівнем амілоїду та депресією при ЦД

A recent study published in *Frontiers in Psychiatry* investigates the relationship between amyloid levels and symptoms of depression and anxiety in individuals experiencing subjective cognitive decline (SCD). Researchers from the Alzheimer Center at VU Medical Center in Amsterdam conducted a longitudinal study involving 329 participants, out of which 88 were amyloid-positive, indicating higher levels of amyloid protein associated with Alzheimer’s disease.

The study assessed depressive and anxiety symptoms over an average period of four years using standardized tools: the Geriatric Depression Scale-15 (GDS), the Center for Epidemiological Studies-Depression (CES-D), and the Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Mixed-effects models were employed to evaluate the associations between amyloid status and these symptoms, considering personality traits such as neuroticism and somatization as possible modifiers.

Findings revealed that amyloid positivity alone did not correlate with increased scores on the GDS, CES-D, or HADS-A. However, personality traits played an important role in modifying these associations. For participants with lower neuroticism levels, amyloid positivity was linked to an increase in GDS scores, indicating greater depressive symptoms. Specifically, the increase was quantified at β:0.10±0.08. In contrast, individuals with higher neuroticism did not show this association, with a change of β:-0.04±0.12.

Similarly, somatization impacted the relationship between amyloid status and CES-D scores. Participants with lower somatization who were amyloid-positive experienced a notable increase in CES-D scores (β:0.65±0.23), whereas those with higher somatization did not show a significant change (β:-0.12±0.29).

These results suggest that individuals with lower neuroticism and somatization who are amyloid-positive may exhibit increased depressive symptoms over time. This phenomenon points to a potential preclinical depression profile related to Alzheimer’s disease pathology. The findings underscore the importance of considering personality traits when assessing mental health symptoms in populations at risk for Alzheimer’s disease.

As the research highlights the complex interactions between biological markers and psychological factors, it opens avenues for further studies aimed at understanding how personality characteristics influence mental health outcomes in cognitive decline. This understanding may ultimately inform preventive strategies or interventions tailored to individuals experiencing subjective cognitive decline.